The case for & against
Bull & Bear analysis
Bearish
Tempus AI, Inc. (NASDAQ: TEM) is a prominent player in the biotechnology sector, specializing in advanced analytics and genomic data for personalized medicine, particularly in oncology. The company operates at the intersection of AI and healthcare, focusing on diagnostic solutions and data applications that contribute to precision medicine initiatives. With a strong emphasis on AI-driven partnerships and data licensing strategies, Tempus AI is positioned to leverage its unique capabilities in a rapidly evolving market, reflecting a broader shift towards data-centric healthcare solutions.
Bull says
- ↑Q1 2026 revenue $348.1M (+36% YoY) with diagnostic sales $261.1M (+35%)
- ↑Raised 2026 guidance to $1.59–$1.60B and secured >$1.1B in contract value
- ↑Proprietary 450PB multimodal dataset enhances AI-driven oncology diagnostics moat
- ↑Strategic pharma partnerships (Merck, Gilead) underpin long-term contract visibility
- ↑Positive analyst revisions and strong liquidity support continued growth momentum
Bear says
- ↓Negative earnings yield and poor profitability scores reflect weak business quality
- ↓Q1 free cash flow fell ~$70M, with recovery dependent on payables normalization
- ↓Extreme stock volatility and elevated short interest raise stability concerns
- ↓Significant insider selling, including by CEO, undermines confidence in outlook
- ↓~40% of licensing revenue from oncology exposes earnings to regulatory shifts
Investment themes with TEM
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR
Julian Komar's Best Winners (Screen Results)↓ -0.50%
NVDA · GOOGL · AVGO
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-09-2026bullish
Transcript signals
Bull points
- they're just another tool in this overall bag of, you know, kind of technology-enabled assets that our physicians increasingly rely on.
- Revenue was $348.1 million, up a little over 36% year over year.
- Our diagnostic revenue was $261.1 million, representing almost 35% growth, driven by particular strength in our oncology business, which had unit growth of about 28%.
Bear points
- If we dialed it up 10x, their cash burn would go up a lot. So we have to meter it, which we're doing which we're doing in close coordination with them.
- we don't expect that to have any impact on pricing or ASPs in 2026.
Read full transcript analysis ›